SAN DIEGO, Aug. 14, 2019 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, today announced a milestone of
10,000 implants of the Precice® system for conditions related to
limb lengthening and reconstruction from NuVasive Specialized
Orthopedics™. The Precice system is an internal nail that once
implanted, utilizes an External Remote Controller (ERC) to
non-invasively lengthen the limb.
"Precice has completely changed the game in limb lengthening and
reconstruction surgery and is rapidly becoming the gold standard of
care for patients with conditions related to limb-length
discrepancy," said Stuart Green, MD,
orthopedic surgeon at UC Irvine School of Medicine. "Before
Precice, patients were limited to bulky, painful external fixation
devices that significantly impacted their mobility and comfort. We
have seen a huge paradigm shift in the last few years with the
adoption of Precice, due to the reliability of the External Remote
Control, the precision of lengthening and compression, patient
comfort, the dramatic reduction of infections and the elimination
of disfiguring scars when compared with external skeletal
fixators."
The Precice system is a state-of-the-art device designed to
eliminate the need for external fixation devices or shortening of
the healthy limb, both of which were previously considered the gold
standard of care for patients with a limb length discrepancy. An
intramedullary nail is implanted into the patient's femur, tibia or
humerus, and is remotely controlled through a complex internal gear
system. Physicians personalize treatment based on the individual
needs of the patient by programming the ERC to perform customizable
lengthening until prescribed correction is achieved. Once
programmed, patients utilize the remote for just seven minutes per
day, and can achieve up to 80mm of limb lengthening throughout the
treatment from the comfort of their own home.
"With over 10,000 devices implanted and more than 30
peer-reviewed clinical studies published since its commercial
release in 2011, Precice has proven to be a validated and preferred
approach to addressing limb length discrepancies by surgeons and
patients alike," said Massimo Calafiore, president of NuVasive
Specialized Orthopedics. "This milestone underscores NuVasive's
commitment to innovate with the mission of transforming the current
standards of orthopedic care."
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
more than $1 billion in revenues,
NuVasive has approximately 2,600 employees and operates in more
than 50 countries serving surgeons, hospitals and patients. For
more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA® platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nuvasive-specialized-orthopedics-reaches-10-000-nail-implant-milestone-of-the-precice-system-for-limb-lengthening-300901205.html
SOURCE NuVasive, Inc.